To include your compound in the COVID-19 Resource Center, submit it here.

Tomtovok afatinib: Phase Ib data

A dose-escalation Phase Ib trial in 22 evaluable patients with EGFR-mutation positive NSCLC who were resistant to treatment with erlotinib or gefitinib showed that once-daily 40 mg afatinib plus

Read the full 291 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE